Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Epidarex Continues Expansion of Its Team

Epidarex Capital, a leading transatlantic early stage life science venture capital firm, is delighted to announce that Russell Makepeace has joined its management team as Vice President of Finance and Administration. Russell is an international business executive with over 25 years of experience in finance, accounting…

NodThera Announces Close of $55 Million Series B Financing

Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital  Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including…

Interim Phase 1 Data Evaluating MOv18 IgE, an Anti-folate Receptor Alpha IgE antibody, in Cancer Patients with Advanced Solid Tumours to be Presented at the AACR Virtual Annual Meeting I

MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer  London, 20 April 2020 – Epsilogen (formerly IGEM Therapeutics), a global leader in the development of immunoglobulin E (IgE) antibodies to…